Skip to Content

Clinical Trial News

This section provides information about recently completed clinical trials. If you cannot find information about a particular clinical trial, you should note that results may not be available even after the trial ends. Some trials end before completion and results are never published.

Moderna Completes Enrollment of Phase 2 Study of its mRNA Vaccine Against COVID-19 (mRNA-1273)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 8, 2020-- Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA)...

Angion Initiates Phase 2 Clinical Trial of ANG-3777 in Patients with Acute Lung Injury Associated with COVID-19 Pneumonia

San Francisco, CA, July 8, 2020 — Angion Biomedica Corp. (Angion), a late-stage biopharmaceutical company focused on the discovery, development, and...

Regeneron Announces Manufacturing and Supply Agreement for BARDA and U.S. Department of Defense for REGN-COV2 Anti-Viral Antibody Cocktail

TARRYTOWN, N.Y., July 7, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that, as part of Operation Warp Speed, the...

Novavax Announces $1.6 Billion Funding from Operation Warp Speed

GAITHERSBURG, Md., July 07, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for...

Expanded Access Protocol Initiated for Compassionate Use of Remestemcel-L in Children With Multisystem Inflammatory Syndrome Associated With COVID-19

NEW YORK, July 06, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that an expanded access protocol (EAP) has been initiated...

Idorsia Announces Positive Results in the Second Phase 3 Study of Daridorexant

Allschwil, Switzerland – July 6, 2020 Idorsia Ltd (SIX: IDIA) today announced positive top-line results of the second pivotal Phase 3 study investigating...

Regeneron Announces Start of REGN-COV2 Phase 3 COVID-19 Prevention Trial in Collaboration with National Institute of Allergy and Infectious Diseases (NIAID)

TARRYTOWN, N.Y., July 6, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the initiation of late-stage clinical trials...

Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-313 in Patients with Tinnitus

SAN DIEGO, July 06, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics...

BELLUS Health Announces Topline Results from its Phase 2 RELIEF Trial of BLU-5937 for the Treatment of Refractory Chronic Cough

LAVAL, Quebec--(BUSINESS WIRE)--Jul. 6, 2020-- BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a...

Gilead Sciences Presents Data Supporting a Potential Six-Month Dosing Interval for Investigational HIV-1 Capsid Inhibitor Lenacapavir (GS-6207)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jul. 4, 2020-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from an ongoing Phase 1 study, which showed that...

EUSA Pharma Announces FDA Approval of Phase 3 Clinical Trial for Siltuximab In Hospitalized Patients with COVID-19 Associated Acute Respiratory Distress Syndrome

HEMEL HEMPSTEAD, United Kingdom & BURLINGTON, Massachusetts – 2 JULY 2020 – EUSA Pharma, a global biopharmaceutical company focused on oncology...

Treatment with Hydroxychloroquine Cut Death Rate Significantly in COVID-19 Patients, Henry Ford Health System Study Shows

DETROIT July 02, 2020 -- Treatment with hydroxychloroquine cut the death rate significantly in sick patients hospitalized with COVID-19 – and without...

Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 study of mRNA-based Vaccine Candidate Against SARS-CoV-2

NEW YORK & MAINZ, Germany--(BUSINESS WIRE) July 01, 2020 -- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced preliminary data from...

Rhythm Pharmaceuticals Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Setmelanotide for Treatment of POMC and LEPR Deficiency Obesities

BOSTON, July 01, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and...

INOVIO Announces Positive Interim Phase 1 Data For INO-4800 Vaccine for COVID-19

PLYMOUTH MEETING, Pa., June 30, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA...

Recombinant Novel Coronavirus Vaccine (adenovirus type 5 Vector) Received Military Specially-Needed Drug Approval in China

Hong Kong, June 29, 2020 -- This announcement is made by CanSino Biologics Inc. (the “Company”) pursuant to Rule 13.09 of the Rules Governing the...

Genmab Announces Very Favorable Topline Results from Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer

Copenhagen, Denmark; June 29, 2020 – Genmab A/S (Nasdaq: GMAB) today announced very favorable topline results from the Phase 2 single-arm clinical trial...

Iterum Therapeutics Announces Topline Results from its Phase 3 Clinical Trial of Oral Sulopenem for the Treatment of Uncomplicated Urinary Tract Infections

DUBLIN, Ireland and CHICAGO, June 29, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on...

Vaxart’s COVID-19 Vaccine Selected for the U.S. Government’s Operation Warp Speed

SOUTH SAN FRANCISCO, Calif., June 26, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc., a clinical-stage biotechnology company developing oral vaccines that are...

Allergan, an AbbVie Company, and Molecular Partners Receive Complete Response Letter from FDA on Biologics License Application for Abicipar pegol

NORTH CHICAGO, Ill., June 26, 2020 /PRNewswire/ -- Allergan, an AbbVie Company (NYSE: ABBV), and Molecular Partners (SIX: MOLN), a clinical-stage biotechnology...

View older articles

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.